Treatment of duchenne muscular dystrophy

摘要

Disclosed is the use of a compound of Formula (I) e.g. 5-(ethylsulfonyl)-2-(naphthalene-2-yl)benzo[d]oxazole in which A1, A2, A3 and A4, which may be the same or different, represent CR1, wherein R1 represents: nitro, halogen, amino or (alkylamino or dialkyl amino ; Y represents N and X represents O, R9 represents - L -R3, in which L is a single bond and R3 is an aromatic mono- or bi-cyclic system; or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the therapeutic and/or prophylactic treatment of Duchenne muscular dystrophy or Becker muscular dystrophy.